Published March 1, 2011 - More info
Cross-reactivity of murine and recently human CD8+ T cells between different viral peptides, i.e., heterologous immunity, has been well characterized. However, the directionality and quality of these cross-reactions is critical in determining their biological importance. Herein we analyzed the response of human CD8+ T cells that recognize both a hepatitis C virus peptide (HCV-NS3) and a peptide derived from the influenza neuraminidase protein (Flu-NA). To detect the cross-reactive CD8+ T cells, we used peptide-MHC class I complexes (pMHCs) containing a new mutant form of MHC class I able to bind CD8 more strongly than normal MHC class I complexes. T cell responses against HCV-NS3 and Flu-NA peptide were undetectable in normal donors. In contrast, some responses against the Flu-NA peptide were identified in HCV+ donors who showed strong HCV-NS3–specific reactivity. The Flu-NA peptide was a weak agonist for CD8+ T cells in HCV+ individuals on the basis of novel pMHCs and functional assays. These data support the idea of cross-reactivity between the 2 peptides, but indicate that reactivity toward the Flu-NA peptide is highly CD8-dependent and occurs predominantly after priming during HCV infection. Our findings indicate the utility of the novel pMHCs in dissecting cross-reactivity and suggest that cross-reactivity between HCV and influenza is relatively weak. Further studies are needed to relate affinity and functionality of cross-reactive T cells.
Victoria Kasprowicz, Scott M. Ward, Alison Turner, Alexandros Grammatikos, Brian E. Nolan, Lia Lewis-Ximenez, Charles Sharp, Jenny Woodruff, Vicki M. Fleming, Stuart Sims, Bruce D. Walker, Andrew K. Sewell, Georg M. Lauer, Paul Klenerman
Original citation: J. Clin. Invest. 2008;118(3):1143–1153. doi:10.1172/JCI33082.
Citation for this corrigendum: J. Clin. Invest. 2011;121(3):1223. doi:10.1172/JCI57501.
Acknowledgment of support from the Oxford Biomedical Research Centre was inadvertently omitted from the Acknowledgments section. The correct sentence appears below.
The study was supported by funding from the NIHR Oxford Biomedical Research Centre programme.
The authors regret the error.